This content is machine translated Psoriasis: System therapies in everyday practice Current real-world data at a glance The better the efficacy of a systemic treatment, the higher the patient satisfaction, especially if the risk-benefit balance is favorable. This plausible correlation is impressively underpinned by current findings from...…
View Post 9 min This content is machine translated Psoriasis: intervening in the inflammatory cascade Advantages of early biologic therapy and oral peptide as a beacon of hope The question of whether early biologics treatment can have a lasting effect on the course of psoriasis is the focus of numerous research projects. The GUIDE study investigated the corresponding...…
View Post 8 min This content is machine translated Psoriasis treatment with biologics What are the latest trends? Novel oral therapies are currently being researched – promising data from clinical trials is now available. In the field of approved, subcutaneously administered IL-23 and IL-17 antagonists, current real-world data...…
View Post 4 min This content is machine translated Guselkumab Study success: application for admission to PsoA submitted New Phase III data from the DISCOVER-1 and DISCOVER-2 studies show improvement in joint and skin symptoms of psoriatic arthritis at week 52, and an indication expansion of guselkumab is…
View Post 3 min This content is machine translated Guselkumab Now also available as a patient-friendly ready-to-use pen The device, which was recently approved by Swissmedic, enables psoriasis sufferers to self-administer the biologic in single doses. It is currently the only IL23 inhibitor available in Switzerland in the…
